<DOC>
	<DOCNO>NCT01008696</DOCNO>
	<brief_summary>The purpose study compare treatment effect rabeprazole lansoprazole depend genotyping ( process determine genetic constitution ) CYP2C19 treat reflux esophagitis ( caused gastroesophageal reflux ; deterioration protective lining inner wall lower esophagus ) ; evaluate cure rate reflux esophagitis endoscopy ( thin flexible tube microscopic camera end pass throat esophagus , stomach , duodenum ) treatment rabeprazole lansoprazole .</brief_summary>
	<brief_title>An Efficacy Study Compare Treatment Effects Rabeprazole Lansoprazole Depending Genotyping CYP2C19 Treating Reflux Esophagitis</brief_title>
	<detailed_description>This prospective ( study follow participant forward time ) , open-label ( people know identity intervention ) , multi-center ( conducted 1 center ) , randomize ( study drug assign chance ) study participant reflux esophagitis . The study include 4 visit : Visit 1 ( Screening period 14 day ) , Visit 2 ( Day 1 ) , Visit 3 ( Day 29+3 ) , Visit 4 ( Day 56 ) . After Screening , eligible participant analyze Visit 2 ( Day 1 ) symptom past week , At visit 3 ( Day 29+3 ) participant randomly assign 1 2 treatment group : rabeprazole 20 milligram ( mg ) lansoprazole 30 mg group . Participants receive rabeprazole 20 mg tablet orally daily 28 56 day lansoprazole 30 mg capsule orally daily 28 56 day . A post-study follow-up visit conduct participant affect serious adverse event within 30 day completion study drug . Participants primarily assess cure rate reflux esophagitis base endoscopy 2 group . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Esophagitis , Peptic</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<criteria>Participants diagnose reflux esophagitis Grade A high Los Angeles ( LA ) classification base endoscopy among participant complain gastroesophageal reflux symptom ( : Heartburn , regurgitation , globus sensation , chronic [ last long time ] cough [ sudden , loud flow air lung ] , epigastric [ area navel ] pain , noncardiac chest pain , hoarseness , dysphagia ) , diagnose reflux esophagitis Grade B high without complain symptom Participants without serious disease except study indication ( reflux esophagitis ) Participants hematology ( related blood ) panel , serum chemistry panel , urinalysis result clinically within twice normal range Female Participants childbearing potential use appropriate contraceptive negative urine pregnancy test Participants serious gastrointestinal disease except reflux esophagitis ( example : digestive tract cancer [ abnormal tissue grow spread body kill ] , hepatic disease , pancreatic disease , ulcer . However , scar ulcer include study target Participants serious concomitant disease ( ) renal disorder , cerebrovascular disease , cardiovascular disease , hepatic disease , severe respiratory disease Participants medical history upper gastrointestinal tract surgery , esophagostenosis , chalasia Participants hematology panel , serum chemistry panel , urinalysis result twice normal range Participants discontinue proton pump inhibitor Histamine 2 antagonist may influence study , 4 week start clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Reflux esophagitis</keyword>
	<keyword>Rabeprazole</keyword>
	<keyword>Lansoprazole</keyword>
</DOC>